



## King's Research Portal

DOI:

[10.1016/j.chest.2024.05.012](https://doi.org/10.1016/j.chest.2024.05.012)

*Document Version*

Peer reviewed version

[Link to publication record in King's Research Portal](#)

*Citation for published version (APA):*

Abu-Sultaneh, S., Prabhu Iyer, N., Fernandez, A., Tume, L. N., Kneyber, M. C. J., López-Fernández, Y. M., Emeriaud, G., & Rose, L. (2024). Framework for Research Gaps in Pediatric Ventilator Liberation. *Chest*, 166(5), 1056-1070. <https://doi.org/10.1016/j.chest.2024.05.012>

### **Citing this paper**

Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination, volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are again advised to check the publisher's website for any subsequent corrections.

### **General rights**

Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the Research Portal

### **Take down policy**

If you believe that this document breaches copyright please contact [librarypure@kcl.ac.uk](mailto:librarypure@kcl.ac.uk) providing details, and we will remove access to the work immediately and investigate your claim.

# Framework for Research Gaps in Pediatric Ventilator Liberation

<sup>Q23</sup> Samer Abu-Sultaneh, MD; Narayan Prabhu Iyer, MBBS, MD; Analía Fernández, MD; Lyvonne N. Tume, RN, PhD; Martin C. J. Kneyber, MD, PhD; Yolanda M. López-Fernández, MD, PhD; Guillaume Emeriaud, MD, PhD; Padmanabhan Ramnarayan, MBBS, MD; and Robinder G. Khemani, MD, MsCI; on behalf of Pediatric Ventilator Liberation Consensus Conference Expert Panel\*, and the Pediatric Acute Lung Injury and Sepsis Investigators Network

**BACKGROUND:** The 2023 International Pediatric Ventilator Liberation Clinical Practice Guidelines provided evidence-based recommendations to guide pediatric critical care providers on how to perform daily aspects of ventilator liberation. However, because of the lack of high-quality pediatric studies, most recommendations were conditional based on very low to low certainty of evidence.

**RESEARCH QUESTION:** What are the research gaps related to pediatric ventilator liberation that can be studied to strengthen the evidence for future updates of the guidelines?

**STUDY DESIGN AND METHODS:** We conducted systematic reviews of the literature in eight predefined Population, Intervention, Comparator, Outcome (PICO) areas related to pediatric ventilator liberation to generate recommendations. Subgroups responsible for each PICO question subsequently identified major research gaps by synthesizing the literature. These gaps were presented at an international symposium at the Pediatric Acute Lung Injury and Sepsis Investigators meeting in spring 2022 for open discussion. Feedback was incorporated, and final evaluation of research gaps are summarized herein. Although randomized controlled trials (RCTs) represent the highest level of evidence, the panel sought to highlight areas where alternative study designs also may be appropriate, given challenges with conducting large multicenter RCTs in children.

**RESULTS:** Significant research gaps were identified in six broad areas related to pediatric ventilator liberation. Several of these areas necessitate multicenter RCTs to provide definitive results, whereas other gaps can be addressed with multicenter observational studies or quality improvement initiatives. Furthermore, a need for some physiologic studies in several areas remains, particularly regarding newer diagnostic methods to improve identification of patients at high risk of extubation failure.

**INTERPRETATION:** Although pediatric ventilator liberation guidelines have been created, the certainty of evidence remains low and multiple research gaps exist that should be filled through high-quality RCTs, multicenter observational studies, and quality improvement initiatives.

CHEST 2024; ■(■):■-■

**KEY WORDS:** airway extubation; clinical protocols; mechanical ventilators; pediatric ICUs; ventilator weaning

**ABBREVIATIONS:** ERT = extubation readiness testing; IMV = invasive mechanical ventilation; NRS = noninvasive respiratory support; PiMax = maximum inspiratory pressure during airway occlusion; POCUS = point-of-care ultrasound; PS = pressure support; QI =

quality improvement; RCT = randomized controlled trial; SBT = spontaneous breathing trial; UAO = upper airway obstruction  
**AFFILIATIONS:** From the Division of Pediatric Critical Care (S. A.-S.), Department of Pediatrics Riley Hospital for Children at Indiana

Liberation from invasive mechanical ventilation (IMV; ie, extubation) is a daily practice in PICUs and pediatric cardiac ICUs worldwide. The first international guidelines for pediatric ventilator liberation were published in 2023 and included 15 recommendations to guide pediatric critical care providers on how to perform different aspects of ventilator liberation.<sup>1-4</sup> Most recommendations were

based on very low to low certainty of evidence largely because of the lack of high-quality studies. The aim of this article is to summarize systematically the research gaps related to pediatric ventilator liberation identified by literature review and the panel of experts. This can be used to set the agenda for future studies to strengthen the quality of evidence for future updates of the clinical practice guidelines.

## Methods

As part of generation of the ventilator liberation guidelines,<sup>1-4</sup> eight Population, Intervention, Comparator, Outcome framework questions were identified related to important aspects of pediatric ventilator liberation. A group of 26 international multiprofessional experts were divided into five subgroups to perform a literature review in each subsection and to craft recommendations. During the synthesis of the evidence, the experts identified key research gaps in each of these subsections. Subsequently, each subsection presented what they believed were the most pressing research gaps to the pediatric critical care community during a symposium at the Pediatric Acute Lung Injury and Sepsis Investigators network spring 2022 meeting. The symposium was attended by 51 pediatric intensive care practitioners in person and 65 such practitioners who attended virtually, many with expertise in pediatric mechanical ventilation because the research priorities for the second Pediatric

Acute Lung Injury Consensus Conference also were presented. Detailed transcription was performed for the entire meeting, and open discussion occurred for each of the priorities. The transcript was provided back to the section leads, who subsequently incorporated feedback from the audience as well as commentary from guidelines experts to identify top research gaps and potential study designs that could address the gaps. The purpose of this article is to provide a framework or outline to help investigators seeking to improve the knowledge base in pediatric ventilator liberation. No specific voting process was carried out to rank the gaps (ie, 1,2,3) because all were believed to be important, and the methods to answer the questions may vary.

To that end, panelists sought to provide practical guidance for how to answer some of these research questions. Although randomized controlled trials (RCTs) represent the highest level of evidence, they require substantial funding, regulatory structure, and collaboration with large multicenter networks. Certainly, each of the research gaps may be answered with a large multicenter RCT, but when appropriate, the panel sought to highlight areas where alternative study designs also may be considered, given the challenges with conducting large multicenter RCTs in children. Hence, the panelists sought to highlight the research gaps where very substantial investment in the form of multicenter RCTs were needed, while proposing alternative study designs such as observational studies or quality improvement initiatives for some of the other research gaps.

In addition, the panelists believed that when studying short-term and long-term outcomes related to pediatric ventilator liberation, pediatric critical care providers need to have a holistic view of the interventions throughout the IMV course starting from the decision to intubate the patient to the decision to attempt liberation. Although our focus is on circumstances around the ventilator liberation attempt, the outcomes are influenced by the entire

University Health and Indiana University School of Medicine Indianapolis, IN; the Fetal and Neonatal Institute (N. P. I.), Division of Neonatology, Children's Hospital Los Angeles Department of Pediatrics, Keck School of Medicine, University of Southern California, the Department of Anesthesiology and Critical Care (R. G. K.), Children's Hospital Los Angeles, University of Southern California Keck School of Medicine, Los Angeles, CA; the Division of Critical Care Medicine (A. F.), Hospital General de Agudos "C. Durand," Universidad de Buenos Aires, Ciudad Autónoma de Buenos Aires, Argentina; the Edge Hill University Health Research Institute (L. N. T.), Ormskirk, the Department of Surgery and Cancer (P. R.), Faculty of Medicine, Imperial College London, London, England; the Division of Paediatric Critical Care Medicine (M. C. J. K.), Department of Paediatrics, Beatrix Children's Hospital, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands; the Pediatric Critical Care Division (Y. M. L.-F.), Department of Pediatrics, Cruces University Hospital, BioBizkaia Health Research Institute, Bizkaia, Spain; and the Department of Pediatrics (G. E.), Sainte-Justine Hospital, Université de Montréal, Montreal, QC, Canada.

\*Collaborators from the Pediatric Ventilator Liberation Consensus Conference Expert Panel are listed in the Acknowledgments.

**CORRESPONDENCE TO:** Samer Abu-Sultaneh, MD; email: [sultaneh@iu.edu](mailto:sultaneh@iu.edu)

Copyright © 2024 American College of Chest Physicians. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.

DOI: <https://doi.org/10.1016/j.chest.2024.05.012>

ventilator course. A conceptual map tying key elements or principles that are important for ventilator liberation to other phases of IMV initially was drafted by a subgroup of panelists including a representative from each of the Population, Intervention, Comparator, Outcome questions and subgroups, the lead and senior authors, and the methodologist. Then,

## Results

The final conceptual map is provided in [Table 1](#). Five areas were identified as important concepts that were believed to increase the risk of extubation failure (upper airway obstruction, respiratory muscle strength, respiratory load, cardiac load, and neuropsychologic factors). We subsequently describe factors from peri-intubation, the IMV course, and ventilator liberation assessment that may impact short-term or long-term outcomes. These short-term and long-term outcomes can be used as core outcomes set for future studies. For example, subglottic suppur airway (UAO) risk may be assessed by the air leak test at the time of ventilator liberation to determine the prescription of periextubation corticosteroids. However, the risk for UAO and the response to corticosteroids also may be affected by the size and type of endotracheal tube used, management of endotracheal cuff during the IMV course, sedation, and delirium management. Similarly, respiratory muscle strength can be affected by ventilator management, sedation, use of corticosteroids, use of neuromuscular blockade, and nutritional status. The pediatric ventilator liberation guidelines focus on evaluating the patient's readiness for an extubation attempt, including measures to quantify risk of complications such as UAO and respiratory muscle weakness as they relate to risk of extubation failure or longer duration of IMV. Thus, this conceptual map is meant to highlight the multitude of other elements that are not in the direct scope of the guidelines, but may influence short-term and long-term outcomes.

## Research Gaps

Herein we summarize the research gaps and priorities related to different elements covered by the pediatric ventilator liberation guidelines.

### *Extubation Readiness Testing Screening and Bundle*

**Rationale 1A:** The expert panel was in 100% agreement that extubation readiness testing (ERT) safety screening should be performed for children intubated for > 24 h.

this was presented and edited by all authors during manuscript review and revisions. As part of the main guidelines, a detailed literature review was conducted, and panelists extracted risk factors for extubation failure. These risk factors then were reviewed by the experts when crafting the guidelines and were used to help inform the conceptual mapping.<sup>5,6</sup>

In most studies included in the guidelines, patients were screened for ERT eligibility daily.<sup>7-14</sup> More frequent evaluation of patients might reduce IMV duration, but also could increase the burden on bedside providers incrementally.<sup>15</sup> However, we found no RCTs comparing frequency of ERT screening (once daily vs more frequent evaluations). Simple checklists with training of the providers might help to avoid excessive burden on bedside providers and increase adherence,<sup>8,10,11</sup> because adherence can be quite low even among trained providers.<sup>12</sup> Alerts in electronic clinical records, computer-driven protocols, or both could improve the adherence to ERT safety screening.<sup>9</sup>

**Research Gaps 1A:** What is the optimal frequency of ERT safety screening that can improve extubation outcomes without significantly increasing the burden on critical care providers? Who are the optimal providers (ie, bedside respiratory therapist, nurse, physician) to perform ERT screening, and is this ICU or country specific? Would adding computerized decision support tools improve the adherence to ERT safety screening?

**Suggested Studies 1A:** Multicenter implementation and quality improvement (QI) studies can investigate multiple questions related to ERT screening and their effectiveness on patient-centered extubation outcomes like time to first successful spontaneous breathing trial (SBT), IMV duration, extubation failure, ICU length of stay, and hospital length of stay.<sup>16</sup> Examples of interventions that can be studied are screening frequency, personnel performing the ERT screening (bedside respiratory therapist vs nurse vs physician), and the use of computerized decision support tools for screening. Compliance rates to ERT safety screening and balancing measures like bedside provider workload should be followed and correlated to the primary outcomes.

**Rationale 1B:** Clinical evaluations included in the ERT safety screening vary from study to study ([Table 2](#)).<sup>7-11,13,15</sup> The optimal ventilator settings that trigger an ERT (ie, positive end-expiratory pressure,

331  
332  
333  
334  
335  
336  
337  
338  
339  
340  
341  
342  
343  
344  
345  
346  
347  
348  
349  
350  
351  
352  
353  
354  
355  
356  
357  
358  
359  
360  
361  
362  
363  
364  
365  
366  
367  
368  
369  
370  
371  
372  
373  
374  
375  
376  
377  
378  
379  
380  
381  
382  
383  
384  
385

**TABLE 1 ] Conceptual Map for Pediatric Ventilator Liberation**

Q18

Intubation	IMV Course	Extubation Attempt	Short-term Outcomes	Long-term Outcomes
<p>Subglottic upper airway obstruction</p> <ul style="list-style-type: none"> <li>• ETT size</li> <li>• ETT type (cuffed or uncuffed)</li> <li>• Intubation process and no. of attempts</li> </ul>	<ul style="list-style-type: none"> <li>• ETT cuff management</li> <li>• Agitation (sedation and delirium)</li> <li>• Fluid overload</li> <li>• Acquired vocal cord paralysis</li> </ul>	<ul style="list-style-type: none"> <li>• <b>Air leak test</b></li> <li>• <b>Peri-extubation corticosteroids</b></li> <li>• <b>NRS use after extubation</b></li> </ul>	<ul style="list-style-type: none"> <li>• UAO</li> <li>• Extubation failure due to UAO</li> <li>• <b>NRS use after extubation</b></li> <li>• New tracheostomy placement</li> <li>• VFDs-28</li> <li>• ICU LOS</li> <li>• Hospital LOS</li> <li>• Mortality</li> </ul>	<ul style="list-style-type: none"> <li>• Subglottic stenosis or other airway anomalies</li> <li>• New tracheostomy placement</li> <li>• PICS-P</li> </ul>
<p>Respiratory muscle strength (respiratory capacity)</p> <ul style="list-style-type: none"> <li>• Use of NRS before intubation</li> <li>• Decision to intubate and timing of intubation</li> <li>• Preexisting respiratory muscle weakness</li> </ul>	<ul style="list-style-type: none"> <li>• VIDD</li> <li>• <b>Sedation assessment and management</b></li> <li>• Delirium assessment and management</li> <li>• NMB use</li> <li>• Fluid overload</li> <li>• Nutrition and electrolytes</li> <li>• Ventilator management</li> <li>• Early mobilization</li> <li>• Acquired diaphragm paresis</li> </ul>	<ul style="list-style-type: none"> <li>• <b>PiMax</b></li> <li>• Diaphragm ultrasound</li> <li>• NRS use after extubation</li> <li>• <b>ERT systematic screening</b></li> <li>• <b>SBT method</b></li> <li>• <b>SBT duration</b></li> <li>• <b>Sedation assessment and management</b></li> <li>• Delirium assessment and management</li> </ul>	<ul style="list-style-type: none"> <li>• Extubation failure because of respiratory muscle weakness</li> <li>• NRS use after extubation</li> <li>• VFDs-28</li> <li>• ICU LOS</li> <li>• Hospital LOS</li> <li>• Mortality</li> </ul>	<ul style="list-style-type: none"> <li>• Prolonged NRS use</li> <li>• New tracheostomy placement</li> <li>• Long-term ventilation</li> <li>• PICS-P (especially muscle weakness and need for rehabilitation)</li> </ul>
<p>Respiratory load</p> <ul style="list-style-type: none"> <li>• Use of NRS before intubation</li> <li>• Decision to intubate and timing of intubation</li> <li>• Severity of initial respiratory disease</li> </ul>	<ul style="list-style-type: none"> <li>• Fluid overload</li> <li>• Timing of resolution of initial disease</li> <li>• VILI</li> <li>• VAE</li> </ul>	<ul style="list-style-type: none"> <li>• Fluid overload</li> <li>• <b>ERT systematic screening</b></li> <li>• <b>SBT method</b></li> <li>• <b>SBT duration</b></li> <li>• SBT pass criteria</li> <li>• <b>NRS use after extubation</b></li> </ul>	<ul style="list-style-type: none"> <li>• Extubation failure because of lung disease</li> <li>• <b>NRS use after extubation</b></li> <li>• VFDs-28</li> <li>• ICU LOS</li> <li>• Hospital LOS</li> <li>• Mortality</li> </ul>	<ul style="list-style-type: none"> <li>• Prolonged NRS use</li> <li>• New tracheostomy placement</li> <li>• Long-term ventilation</li> <li>• PICS-P</li> </ul>

Q19

(Continued)

386  
387  
388  
389  
390  
391  
392  
393  
394  
395  
396  
397  
398  
399  
400  
401  
402  
403  
404  
405  
406  
407  
408  
409  
410  
411  
412  
413  
414  
415  
416  
417  
418  
419  
420  
421  
422  
423  
424  
425  
426  
427  
428  
429  
430  
431  
432  
433  
434  
435  
436  
437  
438  
439  
440

441  
442  
443  
444  
445  
446  
447  
448  
449  
450  
451  
452  
453  
454  
455  
456  
457  
458  
459  
460  
461  
462  
463  
464  
465  
466  
467  
468  
469  
470  
471  
472  
473  
474  
475  
476  
477  
478  
479  
480  
481  
482  
483  
484  
485  
486  
487  
488  
489  
490  
491  
492  
493  
494  
495

TABLE 1 ] (Continued)

Intubation	IMV Course	Extubation Attempt	Short-term Outcomes	Long-term Outcomes
<b>Cardiac load</b> <ul style="list-style-type: none"> <li>• Use of NRS before intubation</li> <li>• Decision to intubate and timing of intubation</li> <li>• Degree of cardiac dysfunction</li> </ul>	<ul style="list-style-type: none"> <li>• Fluid overload</li> <li>• Vasoactive support</li> <li>• Cardiac function</li> <li>• Pulmonary hypertension management</li> <li>• Rhythm control</li> <li>• Surgical correction and residual cardiac lesions</li> </ul>	<ul style="list-style-type: none"> <li>• Monitoring of cardiac output during ERT (ie, perfusion, lactate, NIRS, CVP, echocardiography, dead space fraction)</li> <li>• <b>NRS after extubation</b></li> </ul>	<ul style="list-style-type: none"> <li>• Extubation failure</li> <li>• <b>NRS use after extubation</b></li> <li>• VFDs-28</li> <li>• ICU LOS</li> <li>• Hospital LOS</li> <li>• Mortality</li> </ul>	<ul style="list-style-type: none"> <li>• Prolonged NRS use</li> <li>• New tracheostomy placement</li> <li>• Long-term ventilation</li> <li>• Heart transplantation</li> <li>• Ventricular assist device</li> <li>• PICS-P</li> </ul>
<b>Neuropsychological factors</b> <ul style="list-style-type: none"> <li>• Use of NRS before intubation</li> <li>• Decision to intubate and timing of intubation</li> <li>• Central drive</li> <li>• Neurologic control of the airway</li> </ul>	<ul style="list-style-type: none"> <li>• <b>Sedation assessment and management</b></li> <li>• Delirium assessment and management</li> </ul>	<ul style="list-style-type: none"> <li>• <b>Sedation assessment and management</b></li> <li>• Delirium assessment and management</li> <li>• Withdrawal assessment and management</li> <li>• <b>Ability to control oropharyngeal secretions</b></li> <li>• Spasticity</li> </ul>	<ul style="list-style-type: none"> <li>• Extubation failure</li> <li>• <b>NRS use after extubation</b></li> <li>• VFDs-28</li> <li>• ICU LOS</li> <li>• Hospital LOS</li> <li>• Mortality</li> </ul>	<ul style="list-style-type: none"> <li>• Prolonged NRS use</li> <li>• New tracheostomy placement</li> <li>• Long-term ventilation</li> <li>• PICS-P</li> </ul>

Topics covered by the pediatric ventilator liberation guidelines and research priorities appear in boldface. CVP = central venous pressure; ERT = extubation readiness testing; ETT = endotracheal tube; IMV = invasive mechanical ventilation; LOS = length of stay; NIRS = near infrared spectroscopy; NMB = neuromuscular blockade; NRS = noninvasive respiratory support; PICS-P = post-intensive care syndrome in pediatrics; PiMax = maximal inspiratory pressure during airway; SBT = spontaneous breathing trial; UAO = upper airway obstruction; VAE = ventilator-associated event; VFD = ventilator-free day; VIIDD = ventilator induced diaphragmatic dysfunction; VILI = ventilator-induced lung injury.

496  
497  
498  
499  
500  
501  
502  
503  
504  
505  
506  
507  
508  
509  
510  
511  
512  
513  
514  
515  
516  
517  
518  
519  
520  
521  
522  
523  
524  
525  
526  
527  
528  
529  
530  
531  
532  
533  
534  
535  
536  
537  
538  
539  
540  
541  
542  
543  
544  
545  
546  
547  
548  
549  
550



551  
552  
553  
554  
555  
556  
557  
558  
559  
560  
561  
562  
563  
564  
565  
566  
567  
568  
569  
570  
571  
572  
573  
574  
575  
576  
577  
578  
579  
580  
581  
582  
583  
584  
585  
586  
587  
588  
589  
590  
591  
592  
593  
594  
595  
596  
597  
598  
599  
600  
601  
602  
603  
604  
605

**TABLE 2 ]** Examples of ERT Safety Screening Criteria Used in Pediatric Clinical Studies

Evaluation criteria	Randolph et al <sup>7</sup>	Foronda et al <sup>8</sup>	Jouvet et al <sup>9</sup>	Faustino et al <sup>10</sup>	Abu-Sultaneh et al <sup>11</sup>	Ferreira et al <sup>13</sup>	Loberger et al <sup>15</sup>
Clinical	<ul style="list-style-type: none"> <li>No increased ventilator support in the last 24 h</li> <li>No planned operative procedures in the next 12 h</li> </ul>	An absence of new infiltrates on the CXR		<ul style="list-style-type: none"> <li>A decrease or plateau in ventilator support, or both, over the previous 12 h</li> <li>The acute phase of acute lung injury ends</li> </ul>	<ul style="list-style-type: none"> <li>No increase of ventilator support in the last 24 h</li> <li>No planned procedures in the next 12 h</li> </ul>	<ul style="list-style-type: none"> <li>No signs of significant pulmonary congestion or pleural effusion on CXR</li> <li>Excluded patients with preoperative mechanical ventilation and uncontrolled pulmonary hypertension</li> </ul>	<ul style="list-style-type: none"> <li>No increase in ventilator settings <math>\leq</math> 12 h</li> <li>No planned sedated or surgical procedures in the next 24 h</li> </ul>
IMV settings and gas exchange	<ul style="list-style-type: none"> <li><math>FiO_2 \leq 0.6</math></li> <li><math>PEEP \leq 7</math></li> <li>pH 7.32-7.47</li> </ul>	<ul style="list-style-type: none"> <li><math>FiO_2 \leq 0.5</math></li> <li><math>PEEP \leq 8</math></li> <li><math>PIP \leq 25</math></li> </ul>	<ul style="list-style-type: none"> <li><math>FiO_2 0.6</math></li> <li><math>SpO_2 \geq 95\%</math></li> <li><math>PEEP \leq 8</math></li> <li>Plateau pressure <math>\leq 25</math></li> </ul>	<ul style="list-style-type: none"> <li>OI or OSI <math>&lt; 6</math></li> </ul>	<ul style="list-style-type: none"> <li><math>FiO_2 \leq 0.50</math></li> <li><math>SpO_2 \geq 92\%</math></li> <li><math>PEEP \leq 6</math></li> <li><math>PIP \leq 25</math></li> <li>Vt 6-8 mL/kg</li> </ul>	<ul style="list-style-type: none"> <li><math>FiO_2 \leq 0.50</math></li> <li><math>SpO_2 &gt; 90\%</math> after total corrections or 75%-85% after palliative operations</li> <li>Positive PEEP <math>\leq 5</math></li> <li><math>PIP \leq 20</math></li> <li>pH <math>&gt; 7.3</math></li> </ul>	<ul style="list-style-type: none"> <li><math>FiO_2 \leq 0.5</math></li> <li><math>PEEP \leq 6</math></li> <li><math>PS \leq 10</math></li> <li><math>PIP \leq 30</math></li> <li>Vt <math>&gt; 5</math> mL/kg</li> </ul>
Oxygen availability and consumption	...	<ul style="list-style-type: none"> <li>Hemodynamic stability (doses of sodium nitropruside, dopamine, or dobutamine <math>&lt; 10</math> <math>\mu</math>g/kg/min)</li> <li>Hemoglobin <math>\geq 8</math> g/dL</li> </ul>	<ul style="list-style-type: none"> <li>No vasopressor or inotrope medication (other than digoxin or low-dose dopamine [<math>\leq 5</math> <math>\mu</math>g/kg/min])</li> </ul>	...	<ul style="list-style-type: none"> <li>Hemodynamic stability</li> <li>No increase of vasoactive drips for 12 h</li> </ul>	<ul style="list-style-type: none"> <li>Hemodynamic stability (dopamine <math>&lt; 10</math> <math>\mu</math>g/kg/min or epinephrine <math>&lt; 0.1</math> <math>\mu</math>g/kg/min)</li> <li>Absence of bleeding</li> </ul>	<ul style="list-style-type: none"> <li><math>\leq 1</math> vasoactive infusions and no increases <math>\leq 12</math> h</li> </ul>
Airway protection	Gag or cough with suctioning	...	...	...	...	Intact cough and gag reflexes	...
Electrolytes	...	Correction of electrolyte changes (calcium, magnesium, phosphorus, and potassium)	...	...	...	Absence of electrolyte disturbance	...

(Continued)

606  
607  
608  
609  
610  
611  
612  
613  
614  
615  
616  
617  
618  
619  
620  
621  
622  
623  
624  
625  
626  
627  
628  
629  
630  
631  
632  
633  
634  
635  
636  
637  
638  
639  
640  
641  
642  
643  
644  
645  
646  
647  
648  
649  
650  
651  
652  
653  
654  
655  
656  
657  
658  
659  
660

TABLE 2 ] (Continued)

Evaluation criteria	Randolph et al <sup>7</sup>	Foronda et al <sup>8</sup>	Jouvet et al <sup>9</sup>	Faustino et al <sup>10</sup>	Abu-Sultaneh et al <sup>11</sup>	Ferreira et al <sup>13</sup>	Loberger et al <sup>15</sup>
Neurologic or sedation level	<ul style="list-style-type: none"> <li>Spontaneous breathing</li> <li>Level of consciousness acceptable for extubation</li> </ul>	<ul style="list-style-type: none"> <li>Spontaneous breathing</li> <li>No continuous sedation</li> <li>No use of neuro-muscular blockers in the last 24 h</li> </ul>	Spontaneous breathing	Spontaneous breathing	Spontaneous breathing	<ul style="list-style-type: none"> <li>Adequate respiratory drive</li> <li>Appropriate level of consciousness</li> </ul>	<ul style="list-style-type: none"> <li>No current neuromuscular blockade</li> <li>SBS <math>\geq</math> (-1)</li> <li>GCS <math>\geq</math> 8</li> </ul>
Attending physician approval	Yes	No	No	No	No	Yes	Yes

CXR = chest radiography; ERT = extubation readiness testing; GCS = Glasgow coma scale; OI = oxygenation index; OSI = oxygenation saturation index; PEEP = positive end-expiratory pressure; PIP = peak inspiratory pressure; PS = pressure support; SBS = state behavioral scale; SpO<sub>2</sub> = oxygen saturation; Vt = tidal volume.

FiO<sub>2</sub>, peak inspiratory pressure) are still unclear and warrant additional investigation. Furthermore, some studies include evaluations in a safety screen that might be considered elements of the ERT itself, like sedation level or the presence of gag or cough with suctioning. This makes it difficult to compare outcomes between studies because of a lack of common operational definitions.<sup>7,8</sup> Furthermore, most patients who are identified as high risk for extubation failure in the pediatric ventilator liberation guidelines (like patients with airway, pulmonary, cardiac, and neuromuscular diseases) are underrepresented in existing studies of ERT safety screening, yet these are the patients who are most likely to benefit from ERT safety screening.

**Research Gaps 1B:** What are the optimal thresholds for each of the ERT screening components that can improve ERT bundle performance (like time to first successful SBT) and extubation outcomes? Do these thresholds need to be modified for different patient populations?

**Suggested Studies 1B:** Although RCTs can be created to answer these questions, it is likely that optimal thresholds (aggressive vs conservative) for each of the ERT screening components can be investigated using contemporary observational data from multicenter QI collaborations (Fig 1). For example, different positive end-expiratory pressure thresholds (6 cm H<sub>2</sub>O vs 8 cm H<sub>2</sub>O vs 10 cm H<sub>2</sub>O) and PIP thresholds (20 cm H<sub>2</sub>O vs 25 cm H<sub>2</sub>O vs 30 cm H<sub>2</sub>O) can be tested in different centers comparing patient-centered extubation outcomes (ie, extubation failure and IMV duration).


**Rationale 1C:** ERT bundles have been shown to improve extubation outcomes, but important questions remain about which elements of the bundle are most important, or if the bundle should be expanded to include additional elements.

**Research Gaps 1C:** What elements of the ERT bundle are more predictive of extubation outcomes? Are these elements different for patients at high risk of extubation failure? What additional elements need to be added to ERT bundles to improve bundle performance and extubation outcomes? Does this differ in subpopulations at high risk of extubation failure?

**Suggested Studies 1C:** Given the complexity of conducting large RCTs and the challenges with implementation after an RCT has concluded, it is likely that elements of the ERT bundle suggested in the guidelines can be optimized using contemporary observational data from multicenter QI collaborations.



771 <sup>Q17</sup> Figure 1 – Conceptual framework showing invasive  
 772 mechanical ventilation phases and ERT safety  
 773 thresholds: (1) escalation phase, (2) plateau phase, (3)  
 774 <sup>Q24</sup> de-escalation phase, and (4) liberation phase. ERT =  
 775 extubation readiness testing.



775  
776  
777  
778  
779  
780  
781  
782  
783  
784  
785

786 For example, this can include different thresholds of  
 787 respiratory muscle strength, other methods to assess the  
 788 risk for UAO (like point-of-care ultrasound [POCUS]),  
 789 assessment and management of delirium, and  
 790 assessment and management of fluid overload. In  
 791 addition, the most common reason for SBT failure in  
 792 children relates to high work of breathing. Although this  
 793 commonly is assessed clinically, variability exists in this  
 794 assessment that is practitioner and patient dependent.  
 795 Alternative methods to evaluate respiratory effort or  
 796 work of breathing directly such as esophageal  
 797 manometry (invasive), airway occlusion maneuvers  
 798 (expiratory occlusion pressure, noninvasive), or  
 799 diaphragm ultrasound (thickening fraction) should be  
 800 investigated.<sup>17</sup>

### 803 *SBT Method and Duration*

804 **Rationale 2A:** The guidelines recommend including  
 805 SBTs as an essential element of the ERT bundle.<sup>1</sup> The  
 806 guidelines suggest using either pressure support (PS)  
 807 augmentation with CPAP or CPAP alone during SBTs in  
 808 mechanically ventilated children at standard risk of  
 809 extubation failure. For those at high risk of extubation  
 810 failure, the guidelines suggest using CPAP without PS  
 811 augmentation SBTs for better assessment of extubation  
 812 readiness.<sup>1</sup> This recommendation was based on one RCT  
 813 that showed no significant difference between PS-  
 814 augmented and T-piece SBTs.<sup>18</sup> The drawback of PS-  
 815 augmented SBTs is the underestimation of  
 816 postextubation work of breathing.<sup>19-21</sup> Conversely,  
 817 perceived high work of breathing on CPAP alone  
 818 compared with PS with CPAP may result in delayed  
 819 extubation. A recent open-label, randomized,  
 820 noninferiority trial that was published after the guidelines  
 821 showed that a 2-h PS-augmented SBT was noninferior to  
 822 CPAP alone SBT in predicting successful liberation from  
 823 IMV, although the number of high-risk patients in this

824 study is unclear.<sup>22</sup> Nonetheless, few studies have  
 825 evaluated the effect of PS augmentation on extubation  
 826 success in high-risk populations.

827 **Research Gaps 2A:** What is the optimal method to  
 828 perform SBTs in children? Does the SBT method need to  
 829 be adjusted depending on risk of extubation failure?

830 **Rationale 2B:** Regarding SBT duration, the guidelines  
 831 suggest that the SBT should be conducted for either  
 832 30 min or 60 to 120 min, depending on the patient's risk  
 833 of extubation failure. Obviously, a shorter SBT likely will  
 834 result in more patients passing the SBT, but also likely a  
 835 higher extubation failure rate. In contrast, a longer SBT  
 836 likely will result in lower rates of extubation failure. Since  
 837 the publication of the guidelines, a single-center  
 838 observational study showed that a 30-min SBT might be  
 839 too short in children recovering from pediatric ARDS  
 840 because many go on to fail the SBT at between 30 and  
 841 120 min.<sup>23</sup> Another observational study showed similar  
 842 extubation failure rates for 1-h and 2-h SBTs in a general  
 843 PICU population.<sup>24</sup> However, no pediatric RCTs have  
 844 evaluated SBT duration on extubation outcomes or SBT  
 845 duration in patients at high risk of extubation failure.

846 **Research Gaps 2B:** What is the optimal duration of an  
 847 SBT in pediatric population? Does SBT duration need to  
 848 be adjusted depending on risk of extubation failure?

849 **Suggested Studies 2A and 2B:** Because the SBT method  
 850 and duration are linked intimately, a potential design may  
 851 include a two-by-two factorial RCT. Comparator groups  
 852 could include (1) a PS-augmented SBT vs CPAP alone  
 853 SBT and (2) a 30-min SBT vs a 120-min SBT focused on  
 854 patient-centered clinical outcomes, that is, extubation  
 855 failure and IMV duration. Enrollment can be stratified  
 856 based on extubation failure risk (standard vs high risk).  
 857 Corresponding Population, Intervention, Comparator,  
 858 Outcome questions are summarized in [Table 3](#).

826  
827  
828  
829  
830  
831  
832  
833  
834  
835  
836  
837  
838  
839  
840  
841  
842  
843  
844  
845  
846  
847  
848  
849  
850  
851  
852  
853  
854  
855  
856  
857  
858  
859  
860  
861  
862  
863  
864  
865  
866  
867  
868  
869  
870  
871  
872  
873  
874  
875  
876  
877  
878  
879  
880

TABLE 3 ] Suggested Randomized Control Trials

881	SBT method and duration	936
882		937
883	In children receiving IMV for > 24 h, should SBTs be performed with PS augmentation?	938
884		939
885	P: Children who are intubated for > 24 h undergoing an extubation attempt (stratified into standard risk vs high risk of extubation failure)	940
886		941
887	I: SBT with CPAP of 5 cm H <sub>2</sub> O without PS augmentation	942
888	C: SBT with CPAP of 5 cm H <sub>2</sub> O and PS augmentation between 5 and 10 cm H <sub>2</sub> O	943
889	O: Primary: IMV duration	944
890	Secondary: SBT success rate, extubation failure, ICU LOS, hospital LOS	945
891	Setting: PICU, CICU	946
892		947
893	In children receiving IMV for > 24 h, should SBTs be performed for 30 min or 120 min?	948
894		949
895	P: Children who are intubated for > 24 h undergoing an extubation attempt (stratified into standard risk vs high risk of extubation failure)	950
896		951
897	I: 30-min SBT	952
898	C: 120-min SBT	953
899	O: Primary: IMV duration	954
900	Secondary: SBT success rate, extubation failure, ICU LOS, hospital LOS	955
901	Setting: PICU, CICU	956
902		957
903	UAO risk assessment and prevention after extubation	958
904		959
905	In children receiving IMV for > 24 h with indeterminant risk of UAO after extubation (ie, uncuffed endotracheal tube), should corticosteroids be given before the extubation attempt?	960
906		961
907	P: Children who are intubated for > 24 h with indeterminant risk of UAO after extubation undergoing an extubation attempt (stratified using PiMax into standard risk vs high risk of extubation failure)	962
908		963
909	I: Dexamethasone 0.5mg/kg/dose for 4 doses (maximum, 10 mg) started at least 6 h before planned extubation attempt	964
910		965
911	C: Placebo	966
912	O: Primary: IMV duration	967
913	Secondary: UAO rate, extubation failure, ICU LOS, hospital LOS	968
914	Setting: PICU, CICU	969
915		970
916	NRS after extubation	971
917		972
918	In children receiving IMV for > 24 h who are considered at high risk of extubation failure, should planned BPAP be used immediately after extubation?	973
919		974
920	P: Children who are intubated for > 24 h and considered at high risk of extubation failure undergoing extubation attempt (stratified by age and PiMax)	975
921		976
922	I: Planned BPAP after extubation	977
923		978
924	C: Planned HFNC after extubation	
925	O: Primary: IMV duration	
926	Secondary: extubation failure, ICU LOS, hospital LOS	
927	Setting: PICU, CICU	

BPAP = bilevel positive airway pressure; CICU = cardiac ICU; HFNC = high-flow nasal cannula; IMV = invasive mechanical ventilation; LOS = length of stay; NRS = noninvasive respiratory support; PiMax = maximum inspiratory pressure during airway occlusion; PS = pressure support; SBT = spontaneous breathing trial; UAO = upper airway obstruction.

**Rationale 2C:** Finally, the guidelines did not specify objective criterion for passing an SBT and if this should be adjusted for certain high-risk populations (ie, patients with myocardial dysfunction, neurologic impairment, neuromuscular disease, or chronic critical illness disease).<sup>25</sup> A recent systematic review and meta-analysis showed that the published

assessments have poor prediction of extubation failure in pediatric populations.<sup>26</sup>

**Research Gaps 2C:** What are the optimal criteria that can be used to assess the success of an SBT? What is the optimal threshold of each of these criteria?

991 **Suggested Studies 2C:** An RCT to answer this question  
 992 is likely impractical given the multitude of combinations  
 993 of elements and thresholds. It is likely that high-fidelity  
 994 data from electronic medical records with machine  
 995 learning models from a multicenter QI collaboration can  
 996 be used to study different sets of objective criteria and  
 997 different thresholds and their effect on SBT and ERT  
 998 success rate, extubation failure, and IMV duration.  
 999 Modifications of items included in these criteria and  
 1000 thresholds subsequently can be tested in high-risk  
 1001 populations mentioned above with RCTs or QI  
 1002 interventions. However, it is also clear that passage of an  
 1003 SBT does not always lead to extubation, because  
 1004 clinicians also consider a multitude of other factors  
 1005 before extubation. Certainly, studies focused on clinical  
 1006 decision-making regarding timing of extubation and  
 1007 identifying barriers leading to the delay between passing  
 1008 SBTs and extubation are needed.<sup>27</sup>

### 1011 *Measures of Respiratory Muscle Strength and* 1012 *Function*

1013 **Rationale 3A:** The guidelines suggest the use of  
 1014 maximum inspiratory pressure during airway occlusion  
 1015 (PiMax) as an element of an ERT bundle in critically ill  
 1016 children with risk factors for muscle weakness,  
 1017 extubation failure, or both. The guidelines did not  
 1018 recommend a specific cutoff value for PiMax.  
 1019 Moreover, an international survey of pediatric critical  
 1020 care providers showed that PiMax is not commonly  
 1021 used.<sup>28</sup> No RCTs have shown the impact of using a  
 1022 PiMax threshold to inform extubation decisions.  
 1023 However, existing studies support that a dose-  
 1024 dependent relationship between PiMax and re-  
 1025 intubation risk likely exists, so PiMax should be  
 1026 considered together with other variables that may put  
 1027 the patient at high risk for extubation failure.<sup>29</sup> For  
 1028 example, a PiMax of 25 cm H<sub>2</sub>O in a patient with no  
 1029 other risk factors for extubation failure may not prompt  
 1030 any change in behavior. But if this patient is also at  
 1031 high risk of UAO or has significant residual pulmonary  
 1032 disease, it may inform waiting for further resolution of  
 1033 the pulmonary disease or modulation of the risk for  
 1034 UAO. It may also inform whether the patient should be  
 1035 extubated to noninvasive respiratory support (NRS)  
 1036 prophylactically.

1040 **Research Gaps 3A:** How should PiMax information,  
 1041 gathered as part of an ERT, be used to improve  
 1042 extubation decisions? Does a clear cutoff for PiMax exist  
 1043 that defines patients at high risk of extubation failure  
 1044 where prophylactic extubation to NRS would be helpful?  
 1045

**Suggested Studies 3A:** Because PiMax is measured  
 1046 infrequently in routine clinical practice, the first step  
 1047 likely involves gathering multicenter observational data  
 1048 with routine use of PiMax that can be used to evaluate  
 1049 the independent effect that PiMax has on extubation  
 1050 outcomes. Furthermore, high-quality observational data  
 1051 also can be used to evaluate whether the combination of  
 1052 a low PiMax and other extubation risk factors (such as  
 1053 UAO) leads to even higher rates of extubation failure (ie,  
 1054 an interaction). This may lend itself well to large  
 1055 multicenter QI collaborations in which elements of the  
 1056 ventilator liberation bundle are implemented and PiMax  
 1057 is measured. Stratification of extubation outcomes as a  
 1058 function of PiMax and measurement of potential  
 1059 heterogeneity of treatment effect from implementation  
 1060 of ERT bundle elements (such as periextubation  
 1061 corticosteroids) as a function of various PiMax  
 1062 thresholds may provide more evidence to support using  
 1063 a specific PiMax threshold to inform decision-making or  
 1064 to test in an RCT.

**Rationale 3B:** Although the guidelines focus on  
 1065 assessing the respiratory muscle capacity using PiMax,  
 1066 other potential measures of respiratory muscle strength  
 1067 and function exist, such as diaphragm ultrasound or  
 1068 diaphragmatic electrical activity, that warrant further  
 1069 investigation.<sup>17</sup> Most of the existing data on these  
 1070 techniques have included a relatively small number of  
 1071 patients, and they have not been compared head-to-head  
 1072 with PiMax regarding extubation outcomes.

**Research Gaps 3B:** Would the use of alternative  
 1073 methods to assess respiratory muscle function like  
 1074 diaphragm ultrasound or diaphragmatic electrical  
 1075 activity instead of PiMax improve extubation outcomes?  
 1076

**Suggested Studies 3B:** Observational studies with  
 1077 assessment of the relationship of both PiMax and  
 1078 diaphragm ultrasound (or electrical activity) against  
 1079 extubation outcomes are needed. Because both  
 1080 diaphragm ultrasound and electrical activity require use  
 1081 of specialized equipment, it is likely that these  
 1082 comparative studies would need to begin as smaller pilot  
 1083 projects, and certainly additional physiologic data  
 1084 evaluating the relationship among all these parameters if  
 1085 measured simultaneously also may be helpful.  
 1086

### 1094 *UAO Risk Assessment and Prevention After* 1095 *Extubation*

**Rationale 4A:** Identification of patients at high risk of  
 1096 subglottic UAO after extubation for whom the  
 1097 prophylactic administration of corticosteroids may be  
 1098  
 1099  
 1100

helpful is important because at least one-third of all extubation failures are attributed to UAO after extubation.<sup>30</sup> The guidelines suggest the use of the air leak test in pediatric patients with cuffed endotracheal tubes to assess the risk of subglottic UAO after extubation.<sup>1</sup> However, the air leak test has limitations related to interrater reliability and was not shown to be predictive of UAO after extubation if the endotracheal tube is uncuffed. Other methods of assessment such as upper airway POCUS measuring the difference in laryngeal air column width between an inflated and deflated cuff are being studied, although a relative paucity of pediatric data remains, and this method similarly is meant for cuffed endotracheal tubes.<sup>31-33</sup> Also concerns exist regarding interrater reliability that may be more significant than with the air leak test.

**Research Gaps 4A:** Is upper airway POCUS more accurate than the air leak test at identifying patients at high risk of subglottic UAO after extubation and extubation failure related to UAO?

**Suggested Studies 4A:** Physiologic studies directly comparing these methods against objective measures of UAO after extubation (given that about half of the cases of UAO after extubation are supraglottic) could be an important way to evaluate the initial diagnostic accuracy of POCUS. Larger studies against clinical outcomes such as UAO after extubation will still be limited by lack of an objective marker to differentiate supraglottic from subglottic disease. Outcomes such as reintubation ultimately carry the most clinical impact, but such a study may be impractical given the very large number of patients that would be needed and the limited number of potentially trained practitioners. Ultimately, if upper airway POCUS methods are shown to have more diagnostic accuracy than the air leak test, implementation studies would be crucial to ensure that the technique could be applied broadly for all patients, with adequate training of a large number of practitioners to perform the procedure in each ICU.

**Rationale 4B:** Proper identification of patients at risk of subglottic UAO after extubation allows administration of systemic corticosteroids to prevent subglottic UAO after extubation, potentially reducing the risk of extubation failure. The guidelines suggest that dexamethasone administration initiated at least 6 h before elective extubation may be beneficial in decreasing subglottic UAO after extubation, particularly in high-risk patients.<sup>1,2</sup>

The clinical guidelines identified eight RCTs that served as the basis for a subsequent pairwise and network meta-analysis.<sup>2</sup> The data demonstrate that timing of administration likely is most important (at least 6 h but optimally 12 h) before extubation. If such a time window is not available, then higher-dose corticosteroids likely are preferable than low-dose corticosteroids. Of note, the meta-analysis did show benefit for the outcome of UAO, but not directly for reintubation. Because corticosteroids should be started at least 6 h before extubation, an unintended consequence can be unnecessary delay in extubation, which prompted the guideline committee specifically to suggest targeted use in patients at high risk of UAO. Given the lack of diagnostic accuracy for the air leak test with uncuffed endotracheal tubes, uncertainty remains regarding whether to prescribe corticosteroids for patients with uncuffed endotracheal tubes.

**Research Gaps 4B:** For patients with uncuffed endotracheal tubes, should corticosteroids be prescribed if no other risk factors for UAO after extubation are identified (ie, airway trauma, inappropriately large endotracheal tube)? For patients at high risk of extubation failure resulting from causes other than UAO (ie, respiratory muscle weakness) who have an indeterminant risk of UAO after extubation (ie, uncuffed endotracheal tube), should corticosteroids be used to lower the risk of reintubation?

**Suggested Studies 4B:** An RCT of patients at high risk of UAO after extubation focused on the outcome of reintubation may be clinically important, although multiple RCTs have confirmed that it is useful to reduce the rates of UAO after extubation. Reducing UAO after extubation in itself is important clinically, given that UAO is distressing to the patient and their family, may lead to additional therapeutics and longer ICU stay, and may be associated with long-term adverse outcomes.<sup>34</sup> Hence, this RCT may be a lower priority, given the results of the network meta-analyses.

Significantly more uncertainty in what to do about corticosteroids in patients with indeterminant risk of UAO after extubation remains (ie, uncuffed endotracheal tubes). Here an RCT is likely warranted, with comparison of corticosteroids started at least 6 h before extubation against placebo in children with uncuffed endotracheal tubes. Additional stratification based on risk factors for extubation failure (ie, using PiMax) is important to evaluate potential heterogeneity in treatment effect, particularly for the outcome of reintubation (Table 3).



1211 *NRS After Extubation*

1212 **Rationale 5A:** Planned NRS (NRS started immediately  
1213 after extubation) frequently is used in children to reduce  
1214 the risk of extubation failure. The guidelines suggest  
1215 using planned NRS over conventional oxygen therapy in  
1216 children considered at high risk of extubation failure.<sup>1</sup>  
1217 The list of risk factors of extubation failure was based on  
1218 previously published studies and expert opinion; one key  
1219 risk factor identified in previous literature is prolonged  
1220 IMV before extubation.<sup>35</sup> However, a paucity of  
1221 contemporary multicenter observational studies is  
1222 available to describe the risk of extubation failure  
1223 accurately in different patient groups and to identify  
1224 specific causes of extubation failure. This is particularly  
1225 relevant because the PICU population has changed over  
1226 the past decade, with a rising prevalence of patients with  
1227 complex chronic conditions, in whom the risk of  
1228 extubation failure may be greater.<sup>36</sup>

1232 **Research Gaps 5A:** What factors should be used to  
1233 identify patients who are at high risk of extubation  
1234 failure for whom prophylactic extubation to NRS may be  
1235 warranted?  
1236

1237 **Suggested Studies 5A:** Given many potential risk factors  
1238 for extubation failure, individual RCTs in  
1239 subpopulations are not really feasible. In this case, large  
1240 observational studies with causal inference techniques or  
1241 quasirandomized trials with QI methodology may be  
1242 able to answer this question. In contemporary practice,  
1243 the use of prophylactic NRS is practitioner and  
1244 institution dependent, with very few protocols in place  
1245 to define the population likely to benefit. Analysis of  
1246 observational data may be helpful to identify the  
1247 population at high risk of extubation failure, while  
1248 capitalizing on the variability in treatment decisions by  
1249 using causal inference methods to identify who benefited  
1250 from prophylactic extubation to NRS. Furthermore,  
1251 studying a protocol to use prophylactic NRS before and  
1252 after implementation in a population deemed high risk  
1253 can evaluate which subsets of patients (ie, which risk  
1254 factors) benefited the most from prophylactic NRS.  
1255 PiMax may be an important element to stratify patients  
1256 into standard vs high risk of extubation failure, given  
1257 that patients with impaired respiratory muscle capacity  
1258 are at higher risk of extubation failure.<sup>29</sup> An additional  
1259 important element of such a study includes protocols for  
1260 de-escalating NRS or weaning patients from it, because  
1261 prophylactic use of NRS in fact may prolong ICU stay if  
1262 it is not discontinued or patients weaned from it in a  
1263 timely fashion.  
1264  
1265

**Rationale 5B:** Different methods of NRS are available, 1266  
with high-flow nasal cannula and CPAP being the most 1267  
frequently used.<sup>3</sup> Bilevel positive airway pressure is used 1268  
less frequently, but offers ventilatory assistance, which 1269  
may be important in children with neuromuscular 1270  
disease or ICU-associated muscle weakness. Only one 1271  
large RCT has compared high-flow nasal cannula with 1272  
CPAP after extubation so far<sup>37</sup> and showed that the time 1273  
to liberation from respiratory support was shorter in the 1274  
CPAP group, with a subgroup analysis indicating that 1275  
this was most notable in infants. This informed the 1276  
guideline recommendation that CPAP is suggested to be 1277  
used as the first-line NRS method for children younger 1278  
than 1 year. However, half of the children recruited in 1279  
that RCT were infants, and only small numbers of 1280  
children had cardiac disease or immunosuppression. 1281  
The relative risk to benefit ratio of CPAP as the first NRS 1282  
method in specific subgroups remains unclear, especially 1283  
in children who require ventilatory assistance. The 1284  
increasing prevalence of children with complex 1285  
comorbid conditions, including neurologic and 1286  
neuromuscular diseases, makes this even more 1287  
important. 1288  
1289  
1290

**Research Gaps 5B:** What method of NRS should be 1291  
used as the first-line therapy and how does this differ 1292  
based on risk factors of extubation failure (ie, respiratory 1293  
muscle weakness, residual pulmonary disease, upper 1294  
airway obstruction). 1295  
1296

**Suggested Studies 5B:** An RCT should be conducted in 1297  
children considered at high risk of extubation failure 1298  
comparing the initiation of planned high-flow nasal 1299  
cannula vs bilevel positive airway pressure on extubation 1300  
outcomes. Stratification of these patients can be carried 1301  
out using the list published in the guidelines and data 1302  
can be obtained from multicenter QI collaborations, in 1303  
addition to using PiMax obtained before extubation. 1304  
Planned subgroup analysis can look at different patient 1305  
populations (eg, those who have undergone cardiac 1306  
surgery, those who are immunocompromised, those 1307  
with neuromuscular disease), ages, and centers 1308  
(Table 3). 1309  
1310  
1311

1312 *Sedation Assessment*

**Rationale 6A:** Evaluation of the level of sedation, cough 1313  
effectiveness, and capacity to manage oropharyngeal 1314  
secretions before extubation was suggested as part of 1315  
ERT bundle by the guidelines, and evaluation of level of 1316  
sedation in the periextubation period also was suggested 1317  
by the 2022 Society of Critical Care Medicine PANDEM 1318  
guidelines.<sup>38</sup> 1319  
1320

1321 Two large well-conducted RCTs studied the impact of  
 1322 sedation assessment on pediatric ventilator liberation  
 1323 (namely, IMV duration).<sup>14,39</sup> Although sedation level  
 1324 was a key component of both trials, complexity between  
 1325 sedation assessment or titration and other human factor  
 1326 components of ventilator weaning and extubation in  
 1327 children remains. Both RCTs used bundled  
 1328 interventions (including sedation assessment and  
 1329 management in addition to an ERT component), so it is  
 1330 unclear which one of the bundle components are more  
 1331 important to decrease IMV duration, and neither trial  
 1332 showed a large effect on IMV duration for the  
 1333 intervention. Neither trial examined the impact of  
 1334 delirium, partly because of a lack of validated assessment  
 1335 tools being used at that time.

1337 **Research Gaps 6A:** What is the effect of delirium on  
 1338 pediatric ventilator liberation outcomes?

1339 **Suggested Studies 6A:** Observational studies focused on  
 1340 extubation outcomes should incorporate delirium  
 1341 assessment tools in the periextubation period to identify  
 1342 if delirium has an independent effect on extubation  
 1343 outcomes (IMV duration and extubation failure).

## 1344 Conclusions

1345 Substantial research gaps exist in the field of pediatric  
 1346 ventilator liberation, and although RCTs certainly are  
 1347 needed in many areas, high-quality observational studies  
 1348 and quasirandomized trials also are important to  
 1349 improve the level of certainty behind some of the  
 1350 recommendations and to establish firmer guidelines for  
 1351 what truly constitutes high-risk patients in whom  
 1352 different therapies or strategies may be warranted  
 1353 around the time of ventilator liberation.

1354 Furthermore, for the interventions that are ready for an  
 1355 RCT, a platform trial focused on pediatric patients who  
 1356 have been receiving ventilation for > 24 h may be ideal.  
 1357 In pediatric critical care, many challenges exist to  
 1358 conducting well-powered multicenter RCTs, including  
 1359 heterogeneity of patient populations, relative paucity of  
 1360 patients available to study, and recreation of clinical trial  
 1361 infrastructure for each study, greatly increasing costs. A  
 1362 multicenter platform trial would increase efficiency and  
 1363 would enable simultaneous testing of multiple  
 1364 interconnected elements of pediatric ventilator  
 1365 liberation, iterative cycling through promising  
 1366 interventions in each domain area of ventilator  
 1367 liberation, and risk-based enrollment strata with  
 1368 borrowing techniques between groups to estimate  
 1369 treatment effects better.<sup>40</sup> Although platform trials

1370 certainly are an attractive option to improve efficiency,  
 1371 to increase patient recruitment, and to decrease cost,  
 1372 they do add an extra layer of complexity during study  
 1373 design, need alternative methods for funding, and  
 1374 require unique expertise for adaptation and data  
 1375 analysis.<sup>41</sup>

1376 We hope these guidelines can set the stage for research  
 1377 in pediatric ventilator liberation, but acknowledge  
 1378 important limitations with our approach.

1379 Fundamentally, a great deal of expert opinion remains in  
 1380 this article, particularly related to potential study designs  
 1381 and methods to answer these questions. In addition, the  
 1382 priorities initially were identified by a small group of  
 1383 international experts, and we had limited patient and  
 1384 family representation in the process. We have tried to  
 1385 add rigor to this document and process by basing the  
 1386 gaps on systematic review, presentation of gaps to an  
 1387 international community of pediatric intensive care  
 1388 practitioners and investigators for feedback, and iterative  
 1389 refinement based on feedback the larger community.

1390 In conclusion, we have presented several crucial research  
 1391 gaps in pediatric ventilator liberation and have proposed  
 1392 a conceptual map for how to think about these gaps.  
 1393 This is coupled with suggested methods and study  
 1394 designs to address these gaps, taking into consideration  
 1395 the use of study designs outside of traditional RCTs  
 1396 when they may be applicable. Nevertheless, several  
 1397 crucial areas should be a focus for multicenter RCTs.

## 1400 Funding/Support

1401 The project was funded by Eunice Kennedy Shriver  
 1402 National Institute of Child Health and Human  
 1403 Development National Heart, Lung, and Blood Institute  
 1404 of the National Institutes of Health [Grant  
 1405 R13HD102137], in addition to funds from the  
 1406 Department of Pediatrics at Indiana University School  
 1407 of Medicine.

## 1408 Financial/Nonfinancial Disclosures

1409 None declared.

## 1410 Acknowledgments

1411 **Author contributions:** All authors contributed to the conception or  
 1412 design of the work or in the acquisition, analysis, or interpretation of  
 1413 data for the work. All authors participated in drafting the work or  
 1414 revising it critically for important intellectual content, approved the  
 1415 work, and are responsible for the final version submitted for  
 1416 publication.

1417 **Role of sponsors:** The sponsor had no role in the design of the study,  
 1418 the collection and analysis of the data, or the preparation of the  
 1419 manuscript.



1431 \* **Pediatric Ventilator Liberation Consensus Conference Expert**  
 1432 **Panel Collaborators:** Samer Abu-Sultaneh, MD (Division of Pediatric  
 1433 Critical Care, Department of Pediatrics Riley Hospital for Children at  
 1434 Indiana University Health and Indiana University School of Medicine  
 1435 Indianapolis, IN), Arun Kumar Baranwal, MD (Department of  
 1436 Pediatrics, Postgraduate Institute of Medical Education and Research,  
 1437 Chandigarh, India), Bronagh Blackwood, RN, PhD (Wellcome-  
 1438 Wolfson Institute for Experimental Medicine, Queen's University  
 1439 Belfast, Belfast, Northern Ireland), Hannah J. Craven, MLIS (Ruth Lilly  
 1440 Medical Library, Indiana University School of Medicine, Indianapolis,  
 1441 IN), Martha A. Q. Curley, RN, PhD (Family and Community Health,  
 1442 University of Pennsylvania School of Nursing, and Research Institute,  
 1443 Children's Hospital of Philadelphia, Philadelphia, PA), Guillaume  
 1444 Emeriaud, MD, PhD (Department of Pediatrics, Sainte-Justine  
 1445 Hospital, Université de Montréal, Montreal, QC, Canada), Sandrine  
 1446 Essouri, MD, PhD (Department of Pediatrics, Sainte-Justine Hospital,  
 1447 Université de Montréal, Montreal, QC, Canada), Analía Fernández,  
 1448 MD (Division of Critical Care Medicine, Hospital General de Agudos  
 1449 "C. Durand," Universidad de Buenos Aires, Ciudad Autónoma de  
 1450 Buenos Aires, Argentina), Jose Roberto Fioretto, MD, PhD  
 1451 (Department of Pediatrics, Pediatric Critical Care Division, Botucatu  
 1452 Medical School—UNESP—São Paulo State University, Botucatu, São  
 1453 Paulo, Brazil), Michael Gaies, MD, MPH (Division of Pediatric  
 1454 Cardiology, Department of Pediatrics, University of Cincinnati College  
 1455 of Medicine, and Cincinnati Children's Hospital Medical Center Heart  
 1456 Institute, Cincinnati, OH), Sebastián González-Dambrauskas, MD  
 1457 (Red Colaborativa Pediátrica de Latinoamérica [LAREd Network] and  
 1458 Departamento de Pediatría Unidad de Cuidados Intensivos de Niños  
 1459 del Centro Hospitalario Pereira Rossell (UCIN-CHPR), Facultad de  
 1460 Medicina, Universidad de la República, Montevideo, Uruguay), Silvia  
 1461 M. M. Hartmann, MD (Division of Critical Care Medicine,  
 1462 Department of Pediatrics, Seattle Children's Hospital and University of  
 1463 Washington, Seattle, WA), Justin Christian Hotz, BSRT, RRT-NPS  
 1464 (Department of Anesthesiology and Critical Care, Children's Hospital  
 1465 Los Angeles, Los Angeles, CA), Narayan Prabhu Iyer, MBBS, MD  
 1466 (Fetal and Neonatal Institute, Division of Neonatology, Children's  
 1467 Hospital Los Angeles, and Department of Pediatrics, Keck School of  
 1468 Medicine, University of Southern California, Los Angeles, CA),  
 1469 Philippe Jouvét, MD, PhD (Department of Pediatrics, Sainte-Justine  
 1470 Hospital, Université de Montréal, Montreal, QC, Canada), Martin C. J.  
 1471 Kneyber, MD, PhD (Division of Paediatric Critical Care Medicine,  
 1472 Department of Paediatrics, Beatrix Children's Hospital, University  
 1473 Medical Center Groningen, University of Groningen, Groningen, The  
 1474 Netherlands), Steven Kwasi Korang, MD, PhD (Department of  
 1475 Anesthesiology and Critical Care, Children's Hospital Los Angeles, Los  
 1476 Angeles, CA, and Copenhagen Trial Unit, Centre for Clinical  
 1477 Intervention Research, The Capital Region of Denmark, Rigshospitalet,  
 1478 Copenhagen University Hospital, Copenhagen, Denmark), Yolanda M.  
 1479 López-Fernández, MD, PhD (Pediatric Critical Care Division,  
 1480 Department of Pediatrics, Cruces University Hospital, BioBizkaia  
 1481 Health Research Institute, Bizkaia, Spain), Christopher W.  
 1482 Mastropietro, MD (Division of Pediatric Critical Care, Department of  
 1483 Pediatrics Riley Hospital for Children at Indiana University Health and  
 1484 Indiana University School of Medicine Indianapolis, IN), Natalie  
 1485 Napolitano MPH, RRT-NPS (Children's Hospital of Philadelphia,  
 1486 Philadelphia, PA), Christopher J. L. Newth, MD, ChB (Department of  
 1487 Anesthesiology and Critical Care, Children's Hospital Los Angeles,  
 1488 University of Southern California Keck School of Medicine, Los  
 1489 Angeles, CA), Gerrard F. Rafferty, PhD (Centre for Human and  
 1490 Applied Physiological Sciences [CHAPS], Faculty of Life Sciences &  
 1491 Medicine, King's College London, London, England), Padmanabhan  
 1492 Ramnarayan, MBBS, MD (Department of Surgery and Cancer, Faculty  
 1493 of Medicine, Imperial College London, London, England), Louise Rose,  
 1494 PhD (Florence Nightingale Faculty of Nursing, Midwifery and  
 1495 Palliative Care, King's College London, London, England), Alexandre  
 1496 T. Rotta, MD (Division of Pediatric Critical Care Medicine,  
 1497 Department of Pediatrics, Duke University, Durham, NC), Lyvonne N.  
 1498 Tume, RN, PhD (Edge Hill University Health Research Institute,  
 1499 Ormskirk, England), David K. Werho, MD (Division of Pediatric  
 1500 Cardiology, Cardiothoracic Intensive Care, UC San Diego, Rady  
 Children's Hospital, San Diego, CA), Elizabeth C. Whipple, MLS,  
 AHIP (Ruth Lilly Medical Library, Indiana University School of  
 Medicine, Indianapolis, IN), Judith Ju Ming Wong, MBBCh BAO, MCI

(KK Women's and Children's Hospital, Singapore, Republic of  
 Singapore), and Robinder G. Khemani, MD, MsCI (Department of  
 Anesthesiology and Critical Care, Children's Hospital Los Angeles,  
 University of Southern California and Keck School of Medicine, Los  
 Angeles, CA).

**Disclaimer:** American College of Chest Physician guidelines are  
 intended for general information only, are not medical advice, and do  
 not replace professional medical care and physician advice, which  
 always should be sought for any medical condition. The complete  
 disclaimer for this guideline can be accessed at <https://www.chestnet.org/Guidelines-and-Resources>.

## References

1. Abu-Sultaneh S, Iyer NP, Fernandez A, et al. Executive summary: international clinical practice guidelines for pediatric ventilator liberation, a Pediatric Acute Lung Injury and Sepsis Investigators (PALISI) Network document. *Am J Respir Crit Care Med*. 2023;207(1):17-28. 1497
2. Iyer NP, Lopez-Fernandez YM, Gonzalez-Dambrauskas S, et al. A network meta-analysis of dexamethasone for preventing postextubation upper airway obstruction in children. *Ann Am Thorac Soc*. 2023;20(1):118-130. 1498
3. Abu-Sultaneh S, Iyer NP, Fernandez A, et al. Operational definitions related to pediatric ventilator liberation. *Chest*. 2023;163(5):1130-1143. 1499
4. Iyer NP, Rotta AT, Essouri S, et al. Association of extubation failure rates with high-flow nasal cannula, continuous positive airway pressure, and bilevel positive airway pressure vs conventional oxygen therapy in infants and young children: a systematic review and network meta-analysis. *JAMA Pediatr*. 2023;177(8):774-781. 1500
5. Boles JM, Bion J, Connors A, et al. Weaning from mechanical ventilation. *Eur Respir J*. 2007;29(5):1033-1056. 1501
6. Newth CJ, Venkataraman S, Willson DF, et al. Weaning and extubation readiness in pediatric patients. *Pediatr Crit Care Med*. 2009;10(1):1-11. 1502
7. Randolph AG, Wypij D, Venkataraman ST, et al. Effect of mechanical ventilator weaning protocols on respiratory outcomes in infants and children: a randomized controlled trial. *JAMA*. 2002;288(20):2561-2568. 1503
8. Foronda FK, Troster EJ, Farias JA, et al. The impact of daily evaluation and spontaneous breathing test on the duration of pediatric mechanical ventilation: a randomized controlled trial. *Crit Care Med*. 2011;39(11):2526-2533. 1504
9. Jouvét PA, Payen V, Gauvin F, Emeriaud G, Lacroix J. Weaning children from mechanical ventilation with a computer-driven protocol: a pilot trial. *Intensive Care Med*. 2013;39(5):919-925. 1505
10. Faustino EV, Gedeit R, Schwarz AJ, et al. Accuracy of an extubation readiness test in predicting successful extubation in children with acute respiratory failure from lower respiratory tract disease. *Crit Care Med*. 2017;45(1):94-102. 1506
11. Abu-Sultaneh S, Hole AJ, Tori AJ, Benneyworth BD, Lutfi R, Mastropietro CW. An interprofessional quality improvement initiative to standardize pediatric extubation readiness assessment. *Pediatr Crit Care Med*. 2017;18(10):e463-e471. 1507
12. Krawiec C, Carl D, Stetter C, Kong L, Ceneviva GD, Thomas NJ. Challenges with implementation of a respiratory therapist-driven protocol of spontaneous breathing trials in the pediatric ICU. *Respir Care*. 2017;62(10):1233-1240. 1508
13. Ferreira FV, Sugo EK, Aragon DC, Carmona F, Carlotti A. Spontaneous breathing trial for prediction of extubation success in pediatric patients following congenital heart surgery: a randomized controlled trial. *Pediatr Crit Care Med*. 2019;20(10):940-946. 1509
14. Blackwood B, Tume LN, Morris KP, et al. Effect of a sedation and ventilator liberation protocol vs usual care on duration of invasive mechanical ventilation in pediatric intensive care units: a randomized clinical trial. *JAMA*. 2021;326(5):401-410. 1510
15. Loberger JM, Jones RM, Prabhakaran P. A Respiratory therapist-driven pathway improves timeliness of extubation readiness 1511

- 1541 assessment in a single PICU. *Pediatr Crit Care Med.* 2020;21(8):  
1542 e513-e521.
- 1543 16. Loberger JM, Steffen K, Khemani RG, Nishisaki A, Abu-Sultaneh S.  
1544<sup>15</sup> Implementing the pediatric ventilator liberation guidelines using the  
1545 most current evidence. *Respir Care.* 2024.
- 1546 17. Ito Y, Herrera MG, Hotz JC, et al. Estimation of inspiratory effort  
1547 using airway occlusion maneuvers in ventilated children: a  
1548 secondary analysis of an ongoing randomized trial testing a lung  
1549 and diaphragm protective ventilation strategy. *Crit Care.*  
1550 2023;27(1):466.
- 1551 18. Farias JA, Retta A, Alia I, et al. A comparison of two methods to  
1552 perform a breathing trial before extubation in pediatric intensive  
1553 care patients. *Intensive Care Med.* 2001;27(10):1649-1654.
- 1554 19. Willis BC, Graham AS, Yoon E, Wetzel RC, Newth CJ. Pressure-rate  
1555 products and phase angles in children on minimal support  
1556 ventilation and after extubation. *Intensive Care Med.* 2005;31(12):  
1557 1700-1705.
- 1558 20. Khemani RG, Hotz J, Morzov R, et al. Pediatric extubation readiness  
1559 tests should not use pressure support. *Intensive Care Med.*  
1560 2016;42(8):1214-1222.
- 1561 21. van Dijk J, Blokpoel RGT, Koopman AA, Dijkstra S, Burgerhof JGM,  
1562 Kneyber MCJ. The effect of pressure support on imposed work of  
1563 breathing during paediatric extubation readiness testing. *Ann*  
1564 *Intensive Care.* 2019;9(1):78.
- 1565 22. Vishwa CR, Nallasamy K, Angurana SK, Bansal A, Jayashree M.  
1566 Pressure support versus continuous positive airway pressure for  
1567 predicting successful liberation from invasive ventilation in children:  
1568 an open label, randomized non-inferiority trial. *Lancet Reg Health*  
1569 *Southeast Asia.* 2023;14:100219.
- 1570 23. Knox KE, Hotz JC, Newth CJL, Khoo MCK, Khemani RG. A 30-  
1571 minute spontaneous breathing trial misses many children who go on  
1572 to fail a 120-minute spontaneous breathing trial. *Chest.* 2023;163(1):  
1573 115-127.
- 1574 24. Loberger JM, Watson CR, Clingan EM, Petrusnek SD, Aban IB,  
1575 Prabhakaran P. Pediatric ventilator liberation: one-hour versus two-  
1576 hour spontaneous breathing trials in a single center. *Respir Care.*  
1577 2023;68(5):649-657.
- 1578 25. Miller AG, Brown J, Marshburn O, et al. Factors associated with  
1579 successful extubation readiness testing in children with congenital  
1580 heart disease. *Respir Care.* 2024;69(4):407-414.
- 1581 26. Ng P, Tan HL, Ma YJ, et al. Tests and indices predicting extubation  
1582 failure in children: a systematic review and meta-analysis. *Pulm*  
1583 *Ther.* 2023;9(1):25-47.
- 1584 27. Krasinkiewicz JM, Friedman ML, Slaven JE, Lutfi R, Abu-Sultaneh S,  
1585 Tori AJ. Extubation readiness practices and barriers to extubation in  
1586 pediatric subjects. *Respir Care.* 2021;66(4):582-590.
29. Khemani RG, Sekayan T, Hotz J, et al. Risk factors for pediatric  
extubation failure: the importance of respiratory muscle strength.  
*Crit Care Med.* 2017;45(8):e798-e805.
30. Kurachek SC, Newth CJ, Quasney MW, et al. Extubation failure in  
pediatric intensive care: a multiple-center study of risk factors and  
outcomes. *Crit Care Med.* 2003;31(11):2657-2664.
31. Burton L, Loberger J, Baker M, Prabhakaran P, Bhargava V. Pre-  
extubation ultrasound measurement of in situ cuffed endotracheal  
tube laryngeal air column width difference: single-center pilot study  
of relationship with post-extubation stridor in subjects younger than  
5 years old. *Pediatr Crit Care Med.* 2024;25(3):222-230.
32. El Amrousy D, Elkashlan M, Elshmaa N, Ragab A. Ultrasound-  
guided laryngeal air column width difference as a new predictor for  
postextubation stridor in children. *Crit Care Med.* 2018;46(6):  
e496-e501.
33. Tsai WW, Hung KC, Huang YT, et al. Diagnostic efficacy of  
sonographic measurement of laryngeal air column width difference  
for predicting the risk of post-extubation stridor: a meta-analysis of  
observational studies. *Front Med (Lausanne).* 2023;10:1109681.
34. Green J, Ross PA, Newth CJL, Khemani RG. Subglottic post-  
extubation upper airway obstruction is associated with long-term  
airway morbidity in children. *Pediatr Crit Care Med.* 2021;22(10):  
e502-e512.
35. Gaies M, Tabbutt S, Schwartz SM, et al. Clinical epidemiology of  
extubation failure in the pediatric cardiac ICU: a report from the  
Pediatric Cardiac Critical Care Consortium. *Pediatr Crit Care Med.*  
2015;16(9):837-845.
36. Killien EY, Keller MR, Watson RS, Hartman ME. Epidemiology of  
intensive care admissions for children in the US from 2001 to 2019.  
*JAMA Pediatr.* 2023;177(5):506-515.
37. Ramnarayan P, Richards-Belle A, Drikite L, et al. Effect of high-flow  
nasal cannula therapy vs continuous positive airway pressure  
following extubation on liberation from respiratory support in  
critically ill children: a randomized clinical trial. *JAMA.*  
2022;327(16):1555-1565.
38. Smith HAB, Besunder JB, Betters KA, et al. 2022 Society of Critical  
Care Medicine clinical practice guidelines on prevention and  
management of pain, agitation, neuromuscular blockade, and  
delirium in critically ill pediatric patients with consideration of the  
ICU environment and early mobility. *Pediatr Crit Care Med.*  
2022;23(2):e74-e110.
39. Curley MA, Wypij D, Watson RS, et al. Protocolized sedation  
vs usual care in pediatric patients mechanically ventilated for acute  
respiratory failure: a randomized clinical trial. *JAMA.* 2015;313(4):  
379-389.
40. Woodcock J, LaVange LM. Master protocols to study multiple  
therapies, multiple diseases, or both. *N Engl J Med.* 2017;377(1):  
62-70.
41. PRACTICAL, PANTHER, TRAITS, INCEPT, and REMAP-CAP  
Investigators. The rise of adaptive platform trials in critical care. *Am*  
*J Respir Crit Care Med.* 2024;209(5):491-496.